Pemigatinib is an FGFR1‐, FGFR2‐, and FGFR3‐selective inhibitor and is currently approved for the treatment of previously treated unresectable ICC with FGFR2 fusion.12 This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.